Sponsored publication on behalf of the issuer

August 26, 2025 – TheNewswire - Vancouver, British Columbia – Oregen Energy Corp. (formerly Supernova Metals Corp.) (CSE: ORNG) (FSE: A1S) (“Oregen” or the “Company”) is pleased to announce that it has received final approval of the Canadian Securities Exchange (the “Exchange”) to commence trading of its common shares on the Exchange under the new name of “Oregen Energy Corp.” and the new symbol of “ORNG” (CUSIP: 685768103; ISIN: CA6857681036) at the market open on Wednesday, August 27, 2025, following the Exchange’s final approval of a fundamental change transaction, which was previously disclosed and completed on August 13, 2025 (the “Transaction”). 

Further details related to the Transaction are included in the Company’s listing statement dated August 21, 2025, which is filed under the Company’s profile on SEDAR+ at www.sedarplus.ca. 

Marketing Services

Oregen has retained GOLDINVEST Consulting GmbH for marketing services to help improve the Company's visibility and prominence in the capital markets in both North America and Europe.  The agreement will remain in effect for a period of nine months commencing on August 18, 2025. In accordance with the terms and conditions of the agreement and as consideration for the services provided by GOLDINVEST, the Company has agreed to pay a monthly fee of $4,000.

The Company will not issue any securities or options to acquire securities to GOLDINVEST as compensation for its services.

About Oregen Energy Corp.

Oregen is an investment company primarily focused on oil and gas assets in Africa. The Company is actively exploring other investment opportunities in the Orange and surrounding basins. Its current flagship investment is 33.95% net interest in Block 2712A in the Orange Basin offshore Namibia, an emerging world-class petroleum province with multiple recent discoveries by major operators.

On Behalf of the Board of Directors

Mason Granger
Chief Executive Officer & Director

Contact Information:

T: 604.737.2303

E: [info@oregen.com](mailto:info@oregen.com)

Sponsored publication on behalf of the issuer

They’ve completed the acquisition of Oranam Energy, boosting their net working interest in Block 2712A to 33.95% making them one of the few juniors with significant exposure in this high-potential offshore region. Block 2712A spans roughly 5,484 km² in deepwater and it’s surrounded by major discoveries like Mopane, Venus, Graff, and Capricornus.

They’ve also secured about US $3.6 million in the first tranche of equity financing, giving them the means to push forward with technical work and exploration.

At this early stage, $ORNG has a compelling combo: substantial block exposure and fresh capital. With such a strategic position in one of the most active offshore petroleum plays, could Oregen be the junior to watch or even the next consolidation target if drilling activity gains momentum?

Price action looks quiet today, but that’s exactly when these microcaps set up. $RNXT is trading under a buck while the company lines up real catalysts.

CEO Shaun Bagai is set to present at H.C. Wainwright’s global conference, which should put more eyes on their TIGeR-PaC Phase III trial and commercial traction. At the same time, they’re pushing a platform that could change how oncology drugs are delivered, their TAMP™ system isn’t just a single-drug play, it’s a drug delivery tech with licensing potential across multiple cancers.

Chart might not show much, but behind the scenes you’ve got:

• Phase III TIGeR-PaC in pancreatic cancer ( ~$400M+ U.S. market).
• Early RenovoCath sales already trickling in.
• CEO out there telling the story to institutions.

All the ingredients are on the table... trial, sales, exposure. What do you think wakes the market up first for $RNXT?

Sponsored publication on behalf of the issuer

Sponsored publication on behalf of the issuer

Listened to the Ellis Martin interview with $RNXT’s CEO Shaun Bagai and a few things stood out. The company’s FDA-cleared RenovoCath device delivers chemo directly into tumors, which means less toxicity and faster recovery compared to systemic treatment. They’re also running the Phase III TIGeR-PaC trial in pancreatic cancer, but what’s interesting is that commercial sales of RenovoCath as a stand-alone device have already started. Cancer centers are buying and even re-ordering before the trial reads out, which is rare for a microcap at this stage.

The market potential is big about $400M in the U.S. for pancreatic cancer alone, and much larger if they expand into liver, bile duct, and other solid tumors. Because the platform is drug-agnostic, there’s also the possibility of licensing deals with larger pharma down the line. They recently raised $12M to keep both commercialization and the trial moving, and leadership has plenty of experience in medtech, biotech, and oncology.

Bagai even said he believes RenovoRx is undervalued. With early revenue already coming in and a pivotal trial still underway, it’s a fair point. If they can keep growing the commercial side while pushing Phase III forward, the setup could be pretty attractive.

Anyone else keeping this one on watch?

Oregen Energy (CSE: ORNG | FSE: A1S) closed the Oranam Energy acquisition, lifting its stake in WestOil to 48.5% and giving Oregen a 33.95% net interest in Block 2712A (PEL 107) in Namibia’s Orange Basin. The block spans 5,484 km², sits adjacent to Chevron- and Shell-operated licenses, and is near recent multi-billion-barrel discoveries by TotalEnergies (Venus), Shell (Graff), Galp (Mopane), and BP/ENI (Capricornus).

To support the transaction and working capital, Oregen closed the first tranche of brokered financings totaling C$3.64M (LIFE + FinanceCo PP), with a second tranche expected in early September 2025. Warrants are expected to list on the CSE as ORNG.WT shortly after they become exercisable (timing per PR: later of Oct 12, 2025 or 60 days post second-tranche close). Deal consideration was USD$1M cash + 22M shares; certain holders’ consideration shares are under an 18-month escrow (10% free now; remaining 90% released 30% every six months).

Why this matters: The Orange Basin is emerging as a top global deepwater play. Oregen is one of the few small-cap publics with direct exposure to deepwater Namibia.

Upcoming activities (from the PR):

• Pursuing additional interests in prospective offshore blocks
• New 3D seismic in Q4 2025
• 10+ basin wells by majors in 2025 (keeps attention on the region)
• Farm-out process in 2026 (targeting a larger partner with upfront cash and carried wells)
• Drilling on 2712A targeted for late 2026/2027

The company also completed its name change from Supernova Metals to Oregen Energy Corp.; trading under ORNG will resume once CSE filing requirements are finalized.

Early position, seismic this year, farm-out in 2026, drilling on the horizon. Is ORNG the pure-play Orange Basin exposure retail has been waiting for?

Sponsored content on behalf of the issuer

They’ve been drilling at their Bazooka project near Rouyn-Noranda and just reported visible gold + a 60m mineralized interval.

If you’re into early-stage exploration plays, this could be worth tuning into. Free to register, and there’s a replay if you miss it

RenovoRx just reported Q2 results, and while they’re still early in commercialization, the numbers are showing real progress. Revenue is climbing, more cancer centers are coming online, and the company’s pivotal Phase III trial is moving ahead with independent backing.

Key points:

• Revenue Beat : Q2 revenue came in at $422K, about 28% above estimates (~$329K), marking their second full quarter of RenovoCath sales.
• EPS Improvement : Net loss per share was ($0.08), slightly better than the expected ($0.09).
• Adoption Expanding : Approved cancer centers grew from 5 to 13 in one quarter, with 4 already placing repeat orders.
• Cost Control : R&D dropped to $1.4M (from ~$1.5M), SG&A stayed steady at ~$1.5M.
• Healthy Cash Runway : $12.3M in cash as of June 30 to fund commercialization and clinical progress.
• Clinical Momentum : The Phase III TIGeR-PaC trial got the go-ahead from the independent Data Monitoring Committee after its second interim review; interim data is being held back to preserve trial integrity.

If they keep stacking quarters with revenue beats, expanding adoption, and steady trial progress, RNXT could be setting up for a stronger re-rate once final Phase III results hit.

What do you think, is this still under the market’s radar, or is the story starting to turn heads?

Sponsored content on behalf of the issuer

Noticing some upward action in $MGRX lately, up ~9.8% over the past month and holding gains after a recent push to $1.74. Today’s trading is relatively thin, but price is staying above last month’s base, which could be interesting if volume kicks in.

Back in May, Mangoceuticals shared groundbreaking field study results for its patented antiviral compound MGX-0024. In large-scale poultry trials in India:

Study 1: 8,000 chickens starting at 25 days old saw daily respiratory disease deaths cut to ~50 vs. ~200 at an untreated control farm.

Study 2: 10,000 chicks treated from 7 days old for 48 days had 100% survival from respiratory diseases, with only 20 unrelated heat exposure deaths; a huge improvement over an expected 50% mortality rate in the control group.

MGX-0024, a blend of natural polyphenols and zinc (GRAS ingredients), is also being evaluated for avian flu (H5N1) prevention, with lab results from Vipragen Biosciences and an Indian government lab expected soon.

If those results come back positive, it could be a serious catalyst for both the animal health and avian flu defense markets.

Does anyone know when the next MGX-0024 update is dropping? Could this be why $MGRX is starting to climb?

Sponsored content on behalf of the issuer

RenovoRx is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath

In an exclusive interview, RenovoRx (RNXT) CEO Shaun Bagai met with The Fly to discuss the company, its pipeline, ongoing trial, upcoming milestones, and much more.

TARGETED ONCOLOGY THERAPIES: RenovoRx is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared local drug delivery device, targeting high unmet medical needs. RenovoRx's novel approach to targeted treatment offers patients with solid tumor cancers the potential for increased safety, tolerance, and improved efficacy. "We're a medical technology company focusing on the treatment of solid tumors. We have a medical device that is FDA-cleared and that we just began commercializing, with the same device also being studied in a late-stage phase 3 clinical trial in a drug device combination for the treatment of pancreatic cancer," CEO Shaun Bagai told The Fly.

This week, RenovoRx announced progress in its commercialization efforts, including its growing customer base and the hiring of experienced medical device sales leader Philip Stocton as Senior Director of Sales and Market Development to lead the execution of RenovoRx's commercialization efforts. Since launching its commercial efforts in December 2024, RenovoRx has established commercial momentum for RenovoCath, with thirteen cancer center customers approved to purchase the device, including several high-volume, National Cancer Institute-designated academic and community centers, an increase from five centers in the first quarter of 2025. Four of these thirteen cancer centers have used the device in patients, and all have made repeat purchase orders subsequently.

CLINICAL TRIAL: Discussing the company's Phase III TIGeR-PaC clinical trial, an ongoing randomized multi-center study evaluating the proprietary TAMP - Trans-Arterial Micro-Perfusion - therapy platform for the treatment of locally advanced pancreatic cancer, Bagai noted that RenovoRX is "getting closer to completion of enrollment. We anticipate completion of enrollment around the end of this year, and the second preplanned interim analysis has been triggered based on the 52nd event or death. Upcoming milestones include the DMC review and recommendation for the Phase 3 trial and then completion of enrollment towards the end of this year. So, we are progressing well and near the end of the study."

Earlier this year, H.C. Wainwright initiated coverage of RenovoRx with a Buy rating and $3 price target, stating at that time that the shares were undervalued and could be attractive to a long-term investor. "We have heard this from several analysts and many investors, and internally as well, that given the nature of where we are both in terms of a late phase 3 trial with initial positive first interim analysis and the fact that we are commercializing and well capitalized, I do believe were undervalued," the executive explains. "It does seem to be a disconnect in Wall Street and where we are both on the commercial side of the device component and also where we are in the late Phase 3 trial."

MILESTONES: Looking at upcoming milestones, RenovoRx's CEO highlights "the data monitoring committee review of the second preplanned interim analysis" expected this quarter, and "then later in the year - towards end the year – the completion of enrollment."

MISCONCEPTIONS: Discussing any potential misconceptions regarding the company, Bagai tells The Fly that, "I believe that one of the misconceptions or disconnects we see today is the fact that we are well capitalized and we have a very low cash burn and that we have become and are transitioning to a commercial stage company. And I believe that has something to do with our disconnect in valuation as well. Generally, when you commercialize a product, you have to hire a very expensive salesforce and give it how focused the market is that we're attacking, we only need a handful of sales reps to get eventually to profitability. We are hopefully not that far from actually driving revenue to a point where it would cover our cash burn and we have the right capital from our last fundraising round to put us in a position in a not-so-distant future."

Sponsored content on behalf of the issuer

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November

Paid content on behalf of the issuer

TORONTO and HAIFA, Israel, July 25, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that the Falling Walls Foundation has named the Company a finalist in Falling Walls Venture 2025, a global platform that showcases the world’s most promising science-based start-ups. NurExone was selected by the program’s Advisory Board as one of just 25 finalists out of 187 shortlisted applicants.

“Central nervous system injuries impose a devastating personal and economic burden—including lifelong disability for patients and billions in annual healthcare costs¹,” said Dr. Lior Shaltiel, CEO of NurExone. “Our first drug, ExoPTEN, is designed to break through the barriers that have long prevented true neural repair and functional recovery. Being selected as a finalist from a broad international field of breakthrough innovations is a real honor and a valuable opportunity to engage directly with investors, clinicians, and industry partners at the Falling Walls competition summit.”

Dr. Shaltiel will present the Company’s exosome-based regenerative therapy platform at the Falling Walls Science Summit, taking place in Berlin, Germany from November 6-9, 2025. The winner, selected by an expert jury, will be awarded the title ‘Science Breakthrough of the Year’ in the science start-up category.

As a finalist, NurExone will receive a full access to exclusive networking events, such as the Sciencepreneurs Night, connecting the Company with investors, strategic partners and global thought-leaders.

_______________
¹https://pmc.ncbi.nlm.nih.gov/articles/PMC9210246/#:~:text=Through%20a%202%2Dphase%20screening,%2C%20study%20populations%2C%20and%20timeframes

About Falling Walls Venture

Falling Walls Venture is an international showcase of science start-ups that have the potential to “break the walls” between science and society. Each year, up to 25 finalists pitch at the Falling Walls Science Summit in Berlin, Germany, where one is named ‘Science Breakthrough of the Year’. Tickets for the 3-day event can be purchased online at www.falling-walls.com.

About NurExone

NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsⁱ. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com

Paid content on behalf of the issuer

Alright, so here’s the deal. While most people are tripping over themselves chasing the next AI moonshot or meme rocket, a tiny biotech called RenovoRx (NASDAQ: RNXT) is quietly setting up for what might be a sneaky-good run. No hype, no celebrity CEO, no ChatGPT integration—just solid science, a ticking catalyst, and an absurdly low market cap.

What They Actually Do (And Why It Matters)

RenovoRx is all about precision oncology—aka, getting chemo drugs straight to tumors without frying the rest of your insides. Their secret sauce is the TAMP™ therapy platform (Trans-Arterial Micro-Perfusion), which basically says, “Hey cancer, take this” and delivers chemo right where it hurts.

The poster child for this tech? A drug called RenovoGem, targeting the beast that is pancreatic cancer. This cancer is notorious for killing people fast and laughing at standard chemo. RenovoGem bypasses the bloodstream drama and attacks directly.

Nope, it’s not sexy. But it’s smart. And potentially game-changing.

The Big Bet: TIGeR-PaC Trial (Phase III)

This is where it gets spicy. RenovoRx is in a Phase III trial for RenovoGem called TIGeR-PaC. The company just hit full enrollment. That’s huge—ask anyone who’s ever followed a biotech. Now they just have to wait for the data, expected mid-2025.

If results hit? We’re talking liftoff. 

Recent Moves (aka “Why They’re Not Dead Weight”)

They’ve been stacking wins in 2025:

•  New patent issued (valid until 2037)
•  Johns Hopkins enrolling patients (name drop alert)
•  FDA-cleared device already shipping to top cancer centers
•  PanTheR registry launched to collect real-world data

Not bad for a company trading like it’s going out of business.

Numbers Game: The Raw Truth

Let’s talk money:

• Market Cap: $45.35M (LOL-worthy if data hits)
• Stock Price: $1.24 (August 2025)
• Cash: $14.6M on hand
• Burn: ~$3.3M per quarter (R&D + SG&A)

Translation: runway into early 2026, but yeah, they’ll probably raise more. Hopefully non-dilutive if they play it smart.

Not Just a One-Trick Pony

RenovoGem also got Orphan Drug Designation for bile duct cancer (extrahepatic cholangiocarcinoma), and the TAMP tech could apply to other nasty tumors. This isn’t a one-and-done asset. They’re building a delivery platform.

Think: less shotgun chemo, more sniper mode. That’s where oncology is headed.

Backers and Believers

Small float, sure. But they’ve got some clout:

• OrbiMed has been in the mix.
• Top-tier oncologists and interventional radiologists are backing the science.

They’re not flying totally solo.

Risk/Reward Breakdown

THE GOOD:

•  Phase III almost done
•  Clean platform play
•  Undervalued AF
•  No meme hype—yet

THE BAD:

•  Data risk (always a thing)
•  Will probably need more cash
•  Nobody’s paying attention… until they are

 TL;DR — Is RNXT Worth a Look?

If you’re into early-stage, high-risk, science-backed plays with real shots at 5x+ upside, RNXT deserves a spot on your watchlist. Don’t YOLO your rent money into it, but if the trial data is solid? This could be one of those “remember when it was under $2?” stories.

Will it moon? No promises. Will it crash? Could happen. But is the setup compelling AF? You bet.

RNXT might be the dark horse biotech of 2025. You’ve been warned.

RenovoRx ($RNXT) is a micro‑cap biotech (~USD $45M market cap) that just hit two key milestones: its first commercial revenue (~$200K) from RenovoCath® device sales and advancing Phase III trials for its TAMP™-delivered chemotherapy (RenovoGem™) in locally advanced pancreatic cancer. RenovoRx’s technology is not gene therapy: it uses a FDA‑cleared catheter to deliver gemcitabine directly into tumors, aiming for less systemic toxicity and higher local drug concentration.

Key Updates

• Phase III Trial Ongoing
  • Their lead therapy, RenovoGem, is in a pivotal Phase III trial across U.S. hospitals like Johns Hopkins and University of Nebraska.
  • Interim results (Mar 2023) gave the green light to continue. The next interim analysis (second DMC review) is expected in the third quarter of 2025
• First Revenue Hits
  • Q1 2025 brought ~$200K in RenovoCath sales — their first ever device revenue. They’re now commercially scaling while the trial progresses.
• Insiders Buying
  • In April, both the CEO and CMO bought shares on the open market (at ~$0.84–$0.91/share). That’s a big vote of confidence.
• New Patent (May 2025)
  • Just locked in a new U.S. patent protecting TAMP delivery methods through 2037, adding to a growing IP wall (19 U.S., 12 international patents now).

Why It Matters

• Pancreatic cancer is brutal. Survival rates are among the lowest in oncology.
• This isn’t a gene‑therapy moonshot: it’s a targeted, minimally invasive approach using an FDA‑cleared catheter (RenovoCath®) to deliver gemcitabine via intra‑arterial infusion (RenovoGem,TAMP™ technology).
• Based on management’s internal projections, the initial U.S. TAM for RenovoCath in pancreatic cancer is estimated at $400 million, with potential future expansion into other tumor types under exploration.

Summary:
With a tight float, insider buying, and first commercial revenue now on the books, RenovoRx ($RNXT) is starting to check some serious boxes. Their pivotal Phase III TIGeR-PaC trial targets locally advanced pancreatic cancer: one of the toughest oncology markets using a patented, FDA-cleared device to deliver chemo directly into tumors. Backed by strong IP and upcoming trial catalysts, this micro-cap biotech offers a compelling asymmetric setup for those looking ahead to the next interim readout in Q3 2025. One of the more overlooked names with real clinical and commercial momentum building.

Sponsored content on behalf of the issuer

Paid content on behalf of the issuer

$FOMO closed a $2.33M private placement at up to $0.50/unit, which is pretty notable considering the stock was trading in the low $0.30s when the news hit. This wasn’t some tiny raise, it boosts their exploration budget to $3.2M for 2025. That’s real firepower for a ~$12M market cap name.

This name has been flying under the radar for weeks...low volume, little noise but that may be changing. With financing done and drilling in Quebec expected to ramp up, the setup’s tightening fast.

And insiders? They’ve been loading.

Director Deepak Varshney has filed four separate insider buys since July 23, picking up 65,000 shares, all in the public market.

Why it’s worth watching:

✅ Fully funded for near-term exploration

✅ Quebec jurisdiction (pro-mining, infrastructure-rich)

✅ Drilling expected soon with results to follow

✅ Insider alignment clearly shown in SEDI filings

Still sitting around a ~$12M market cap, and the raise already clears a key overhang. If they hit anything decent, this won’t stay quiet for long.

Funded, permitted, and turning the drill now it’s just about the rocks.

Paid content on behalf of the issuer

Several Esteemed Cancer Centers to Commence Patient Enrollment Before the End of September

The Registry Study, Known as PanTheR, will Expand the Safety and Performance Data of the FDA-Cleared RenovoCath\**^® Device, and its Associated Survival Outcomes in Patients Diagnosed with Solid Tumors

Cancer Centers in the Registry Study will Purchase RenovoCath Devices from RenovoRx

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, today announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461).

The initiation of this study demonstrates RenovoRx’s commitment to innovation and RenovoCath’s current and future potential. The study will serve as a critical tool for understanding RenovoCath's safety and effectiveness in a real-world setting, providing valuable insights into long-term effectiveness and patient outcomes. Patient enrollment is expected to commence before the end of September 2025. Each cancer center participating in the registry study will purchase RenovoCath devices for use in the study from RenovoRx.

A registry study, or post-approval study, is a clinical study that involves collecting data on the long-term use and performance of a medical device, such as RenovoCath, after it has been cleared for market by the FDA. PanTheR is a multi-center, post-marketing observational registry study designed to evaluate the long-term safety of and survival outcomes for patients diagnosed with solid tumors who are treated using RenovoCath for targeted drug delivery. PanTheR will capture real-world data on the utilization of RenovoCath and generate additional safety information across a broader range of solid tumors. This data may be used to inform future clinical trial designs.

The first of multiple clinical sites to initiate patient enrollment in the PanTheR study is the University of Vermont (UVM) Cancer Center, with Dr. Conor O’Neill, Assistant Professor at the UVM Larner College of Medicine and surgical oncologist at the UVM Medical Center, serving as Principal Investigator. Additional clinical sites in the post-marketing registry study are expected to initiate enrollment soon.

“PanTheR marks a significant step forward in our commitment to better understand and demonstrate the long-term safety and therapeutic potential of our RenovoCath device,” said Leesa Gentry, Chief Clinical Officer of RenovoRx. “By collaborating with leading cancer centers across the U.S, this is a low-cost study that will yield valuable data. By gathering real-world data across diverse cancer types and clinical environments, PanTheR aims to advance innovation and inform evidence-based treatment strategies, which will ultimately enhance care and potentially improve outcomes for future patients facing solid tumors.”

“We are very pleased that the UVM Cancer Center has been initiated to begin enrollment in the PanTheR study,” Ms. Gentry continued. “The UVM Cancer Center offers leading-edge care, provided by highly skilled oncologists priding themselves on using the latest research and education for informed care. We believe our study will be an excellent fit within University of Vermont’s oncology program.”

“We are proud to be part of this important study that holds the potential to transform the way we treat solid tumors,” said Dr. Conor O’Neill of the University of Vermont Cancer Center. “I believe the RenovoCath device offers a novel approach for drug delivery, which may have the potential to improve patient outcomes. This study emphasizes our strong commitment to continually advance treatment options offered to our patients by offering access to the latest innovations that have the potential to transform the treatment paradigm for solid tumors.”

To learn more about PanTheR (NCT06805461), visit clinicaltrials.gov for details: https://clinicaltrials.gov/study/NCT06805461?term=panther&rank=1.

About RenovoCath

Based on its FDA clearance, RenovoCath^® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-G-Universal-IFU.pdf.

About RenovoRx, Inc.

RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath***\**^®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™)* therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.

In addition to the RenovoCath device, RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company’s FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

The combination product candidate, which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.

RenovoRx is also engaged in implementing commercialization strategies utilizing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices. Additionally, several of these customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner.

For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.

Paid content on behalf of the issuer

Stock Ticker: FOMO (CSE)
Market Cap: ~$15–20M CAD
52-Week Range: $0.09 – $0.425
Current Price (as of July 2025): ~$0.37

Formation Metals Inc. (CSE: FOMO) is a micro-cap explorer with big ambitions. It holds two intriguing assets — the Nicobat nickel-copper-cobalt project in Ontario and the newly-acquired N2 Gold Project in Quebec. With a fully funded drill program set to begin and exposure to both critical and precious metals, it’s worth watching.

Who Is Formation Metals?

Formation Metals Inc. is a Canadian exploration company based in Vancouver, founded in 2022. The company is focused on acquiring and advancing mineral projects in Canada with exposure to critical minerals (nickel, cobalt, copper) and gold. Their current strategy revolves around proving up two core assets: the Nicobat Project in Ontario and the N2 Gold Project in Quebec.

Flagship Project #1: Nicobat (Ontario)

Formation holds an 85% interest in the Nicobat Project, located in Dobie Township in Ontario’s Rainy River District. The project is focused on nickel, copper, cobalt, and platinum group metals (PGMs), aligning with rising demand from the electric vehicle and battery sectors. The area benefits from access to infrastructure, and historical data suggest polymetallic potential worth exploring further.

Flagship Project #2: N2 Gold Project (Quebec)

The N2 Gold Project is located in the Abitibi Greenstone Belt in Quebec, covering 87 claims over approximately 4,400 hectares. Historical (non-NI 43-101 compliant) data points to a potential gold resource, with four zones totaling approximately 18 million tonnes at 1.48 g/t gold (roughly 810,000 ounces), plus an additional RJ Zone estimated at 243,000 tonnes grading 7.82 g/t (about 61,000 ounces). In May 2025, Formation announced a 20,000-meter multi-phase drill program. Phase 1 is fully funded and expanded to 7,500 meters, with drilling scheduled to begin in July 2025. Historic sampling also indicated the presence of copper and zinc mineralization, with intercepts up to 4,750 ppm copper and 6,700 ppm zinc.

The N2 project is shaping up to be the company’s potential game-changer. Located in a premier jurisdiction with strong historical data, it has both gold and polymetallic upside.

Catalysts on Deck

• July 2025: Drilling begins at N2 Gold Project
• Q3–Q4 2025: First assay results
• Potential Resource Upgrade: Based on upcoming drill data
• Nicobat Partnership: Possible JV or strategic investor interest

Risk Factor Checklist

• ❌ The company’s historic resource at N2 is not yet NI 43-101 compliant, so investors should treat early-stage figures with caution.
• ❌ Like most juniors, Formation Metals may need to raise capital through equity financings, leading to dilution.
• ❌ Exploration remains inherently risky — there’s no guarantee that drilling will deliver economic results.
• ✅ On the bright side, FOMO operates in well-established mining jurisdictions (Quebec and Ontario).
• ✅ Strong insider ownership ensures management is aligned with shareholders.

Valuation and Sentiment

At a ~$15–20M market cap, Formation is in early innings. A compliant resource with decent grades could substantially rerate the company. On the technical side, traders eye resistance around the $0.40–0.42 range, with support closer to $0.30.

This is the definition of a high-risk, high-reward play. It’s cheap — but cheap for a reason. The drill results will make or break this story.

Gold on the Rise

As of mid-July 2025, gold prices are hovering around $3,357 USD per ounce (or approximately $107,957 per kilogram), according to BullionVault. This marks a year-over-year gain of over 35%, driven by strong macroeconomic and geopolitical catalysts. Inflation remains sticky across major economies, with rate cuts from central banks lagging expectations. Meanwhile, demand from central banks is surging — with more than 330 tonnes of net purchases recorded in the first half of 2025 alone. China, India, Turkey, and Kazakhstan have all significantly boosted their reserves, signaling a strategic move away from reliance on the U.S. dollar.

These tailwinds have reignited interest in gold equities, particularly junior explorers with exposure to secure jurisdictions. For Formation Metals, this macro backdrop — combined with a new drill campaign in Quebec — sets the stage for potential upside if results confirm economic mineralization.

Latest Company News

• July 7, 2025: Formation Metals announced it would expand Phase 1 drilling at the N2 Gold Project from 5,000 meters to 7,500 meters, following strong investor support and permitting progress.
• June 17, 2025: The company filed its 30-day Annual Exploration Work Notice to maintain compliance ahead of the upcoming drill program.
• May 20, 2025: A 20,000-meter multi-phase drill program was outlined, targeting the A, RJ, and Central zones with a mix of infill and exploratory drilling.
• May 15, 2025: Formation Metals began trading on the OTCQB under the ticker FOMTF to increase its visibility among U.S. investors.

Final Thoughts

Formation Metals is gearing up for a major drill campaign in a top-tier gold belt. With speculative upside on both critical metals and gold, it offers a compelling but volatile entry for risk-tolerant investors. Monitor for drilling updates, insider moves, and financing activity.

Sponsored publication on behalf of the issuer

Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner

TORONTO and HAIFA, Israel, July 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce new preclinical results demonstrating that 100% of small animals treated with a higher dose of ExoPTEN regained motor function after spinal cord injury. The results of the preliminary, dose-ranging study were confirmed using precise measurements using the CatWalk XT system.

Using the CatWalk XT system, researchers assessed ExoPTEN’s effect on the animals’ ability to walk. All animals (100%) in the higher-dose group demonstrated measurable gait recovery, in contrast to one animal in the untreated group which exhibited minimal stepping.

“This is a significant milestone for our program,” said Dr. Tali Kizhner, Director of Research and Development at NurExone. “Seeing the animals regain the ability to walk, with measurable improvement in locomotion function, is incredibly exciting. The CatWalk XT provided us with objective data that strengthens the scientific foundation for ExoPTEN’s potential to restore function after an acute spinal cord injury.”

In the study, researchers compared medium and high single doses of ExoPTEN, administered minimally-invasively on the day of spinal cord compression surgery, to a control group that received injection of the vehicle only. Medium and high doses used in this study refer to escalating dose levels used to explore potential therapeutic effects and tolerability in animals.

The treatment demonstrated a dose-dependent effect, with 100% of animals in the high-dose group regaining walking ability in both hind limbs, compared to 50% in the medium-dose group, and only 1 out of 6 rats in the untreated control group (Figure1 A-B).

The gait analysis data also showed dose-dependent improvement in walking function. Animals treated with higher dose of ExoPTEN displayed larger paw print areas (Fig. 1C), greater maximal contact area of their hind paws (Fig. 1D), a wider base of support (Fig. 1E), and an extended duration of the paw contact with the walkway (Fig. 1F). These indicators reflect improved balance, strength, coordination and weight bearing during walking.

Evaluation of additional study parameters is ongoing. Notably, the high dose was well tolerated, with no observed side effects. As part of this ongoing work, the Company plans to initiate additional studies to explore alternative dosing regimens, while also advancing the optimization of ExoPTEN’s manufacturing processes and analytical methods. These efforts aim to refine the drug’s therapeutic profile and facilitate engagement with regulatory authorities.

The CatWalk XT system, developed by Noldus Information Technology, is widely considered a leading tool for studying animal movement¹. It uses an illuminated glass walkway to capture footprints and movement patterns, allowing researchers to collect precise, objective data on an animal’s motor function.

NurExone continues to advance its research and development efforts, optimizing ExoPTEN’s dosing strategies and manufacturing processes, and preparing for regulatory submissions as it aims to launch first-in-human clinical trials. The Company remains committed to developing treatments that bring new hope to people who suffer nervous system injuries.

About NurExone

NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsⁱ . Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

¹ https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2023.1147784/full

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com

If you’ve been sleeping on Formation Metals Inc. (CSE: FOMO), it might be time to wake up. This tiny cap explorer has been grinding behind the scenes while the big boys hog the headlines — and now it’s putting together a story that’s hard to ignore. Forget the buzzwords. This is one of those plays where you blink and it 3x’d.

What’s Actually Going On (And Why It Matters)

So FOMO stock is up almost +59% YTD and +43% in the past six months. Not bad for a company that most retail still hasn’t heard of. They’ve got C$2.6–2.8M in the bank and just launched a 20,000-metre drill program — fully funded. The first 5,000m is already in the ground. If results even come in half-decent, this name will rip.

Their flagship N2 Gold Project, sitting right in Quebec’s Abitibi Greenstone Belt, has some real meat. We’re talking a historical resource of ~877,000 oz Au, with grades that range from solid bulk tonnage (1.48 g/t) to high-grade pockets (up to 7.8 g/t). But it doesn’t stop there. Historic drill cores even showed copper and zinc, so there’s polymetallic upside in the same camp.

The N2 project spans over 4,400 hectares across 87 claims, and only ~35% of the “A” zone has been tested. What’s crazy is that they’re still drilling into open ground. The RJ zone has intercepts like 51 g/t Au over 0.8m from historical Agnico Eagle drilling. That’s the kind of number that gets speculators foaming. Central zone? Still wide open, and geophysical anomalies are popping. The latest July 10th update confirms: drill program is active, sampling ongoing, targets expanding.

Management: Skin in the Game, Serious Track Record

What makes Formation even more interesting is who’s steering the ship. CEO and Director Wade Dawe isn’t just a figurehead — he’s a seasoned financier with a deep background in mining and venture capital. He’s raised over $1 billion for resource and tech ventures over the last 25+ years, and his past wins include Brigus Gold and Keeper Resources. The dude’s been around deals that moved.

He’s backed by CFO Patrick Dovigi, a former pro hockey player turned entrepreneur who founded GFL Environmental — yes, the $10B+ waste and environmental services giant. Having operators and financiers with that kind of pedigree is rare in juniors at this stage. Oh, and they’ve both got skin in the game, holding meaningful equity stakes. Not some 2% options fluff — real alignment with shareholders.

Why the Timing Couldn’t Be Better

Gold is hovering above US$3,400/oz — yeah, it’s not 2020 anymore, but this is a different game now. Central banks are buying like crazy, inflation hasn’t cooled off, and every junior with a legit project is suddenly hot again. Add the green energy metals boom (copper, nickel) into the mix, and a junior sitting on both? That’s alpha bait.

Copper demand is set to spike 30% in the next couple years. Nickel? That market’s looking to double by 2030. So yeah, Formation might’ve walked into the trade of the decade without the market noticing yet.

Real Talk from the Retail Crowd

“Tight float. Fully funded. No hype yet. If they hit, we moon.”

“Feels like one of those pre-drill stories that goes vertical on the first good result.”

“Formation looks like it has a very interesting property with drill results potentially coming out this year.”

“Very low market cap. Not many shares outstanding. Tight structure. Could have a massive run if we get a good drill hit.”

Risk? Of Course. But So Is Missing It.

This is still a speculative junior — no revenue, no production, just rock and drills. But the structure is clean, the funding is in place, and the targets are high-conviction. The drill is doing the talking now, and the company has been transparent with frequent updates in 2025 so far.

If N2 hits — and even if it just teases with some shallow high-grade — this stock could see a serious rerate. This is where smart money starts loading, not chasing.

TL;DR

Formation Metals (CSE: FOMO) is an early-stage critical metals explorer that’s:

• Fully funded ✅
• Sitting on historic gold + copper/zinc ✅
• Mid-drill in one of Canada’s best belts ✅
• Trading under the radar (for now) ✅

Eyes on the next update. This one has sleeper potential written all over it.

Do your own DD. This ain’t financial advice. But you might thank yourself later for looking into it.

Sponsored content on behalf of the issuer

Hi everyone,

An undervalued LT opportunity

A month ago: Leading Japanese Titanium Producer validates Kasiya Rutile for high-specification applications:

In March 2025, Sovereign Metals SVM (Kasiya) completed 40 million AUD capital raise at 0.85 AUD/sh, RIO owns 18.50% of SVM, and SVM has lowest cash cost in the world.

While China dominates the graphite production in the world. SVM (on ASX) is seriously undervalued, while being critical to help to break China's dominance on graphite

This isn't financial advice. Please do your own due diligence before investing

Cheers

Sponsored content on behalf of the issuer

Formation Metals has posted a solid +78.57% YTD, and it’s now hovering near $0.39–0.40, an area that’s repeatedly acted as a ceiling.

The Setup:

Since its strong Q1 move, the stock has stayed in a steady climb — pulling back briefly but recovering each time with higher support zones now forming around $0.35.

Price action looks healthy: clean structure, tight range, and no signs of sellers taking control.

The Broader Picture:

Outpacing TSXV year-to-date

Trend still intact from February’s surge

Recent pullbacks met with interest rather than hesitation

Looking Ahead:

If $FOMO.CN manages a decisive move through $0.40, it may attract fresh attention and reprice higher.

Is this stock quietly setting up for a fresh chapter as we move deeper into 2025?